Program

Each session will feature 10-minute presentations coupled with 5-minute Q&As and ending with 20-minute panel discussions. All times below are in US Eastern Time – to review times in your own time zone, please use the green buttons below.

A PDF version of the program is available for download from the right.

DxA_Program_2020

PROGRAM AT-A-GLANCE

See DAY 1 date/times in your time zone See DAY 2 date/times in your time zone See DAY 3 date/times in your time zone

Wednesday, October 7, 2020
SESSION I	Ocular and Emerging Protein Biomarkers of ADRD, Biomarkers for FTD	CO-CHAIRS: Robert Dean, MD, PhD, Robert A. Dean Consulting Tetsuyuki Maruyama, PhD, KPY Consulting
10:00-10:05	Welcome & Introductory Notes	Howard Fillit, MD, Alzheimer's Drug Discovery Foundation
10:05-10:10	Session Overview	CO-CHAIRS: Robert Dean, MD, PhD, Robert A. Dean Consulting Tetsuyuki Maruyama, PhD, KPY Consulting
10:10-10:25	Delivering Novel Neuro-retinal Biomarkers for the Early Diagnosis of Alzheimer's Disease	Thomas MacGillivray, PhD, University of Edinburgh
10:25-10:40	Findings from the RetiSpec Hyperspectral Imaging System in Individuals with Preclinical and Early Alzheimer's Disease: A Preliminary Report	Eliav Shaked, MSc, RetiSpec Catherine Bornbaum, PhD, MBA, RetiSpec
10:40-10:55	Fully Automated Plasma Assays as Screening Tests for Alzheimer-related Amyloid Beta Pathology	Henrik Zetterberg, MD, PhD, University of Gothenburg
10:55-11:10	Plasma Abeta as a Predictor of Amyloid Positivity in Alzheimer's Disease	Stephen Zicha, PhD, Foundation for the National Institutes of Health Wesley Horton, MS, Foundation for the National Institutes of Health
11:10-11:25	Tau and p-tau as Alzheimer Biomarkers - Assays, Methodological Aspects and Clinical Performance	Kaj Blennow, MD, PhD, University of Gothenburg
11:25-11:40	TABLOOD: a Biomarker Panel for Direct Assessment in Blood of Alzheimer's Disease Pathophysiological Hallmarks	Douglas Galasko, MD, University of California San Diego
11:40-12:00	QUESTIONS and DISCUSSION	Robert Dean, MD, PhD, Robert A. Dean Consulting
12:00-12:05	BREAK
12:05-12:20	Studies on the Plasma Contact System in Alzheimer's Disease	Sidney Strickland, PhD, The Rockefeller University Erin Norris, PhD, The Rockefeller University
12:20-12:35	Novel Platform for On-Chip Detection of Neuronal Extracellular Vesicle-Bound Peripheral Biomarkers for Alzheimer’s Disease and Other Dementias	Amber Murray, PhD, Biological Dynamics
12:35-12:50	Validation of Blood-based Biomarkers for the Detection of Brain Amyloid Accumulation before Clinical Onset of Dementia	Blaine Roberts, PhD, Emory University
12:50-13:05	Protein Misfolding Cyclic Amplification (PMCA) Clinical Test for Detection of Aggregates of Misfolded α-Synuclein	Russell Lebovitz, MD, PhD, Amprion Inc.
13:05-13:20	Blood Biomarker Monitoring in Frontotemporal Lobar Degeneration: Neurofilament Surveillance Project (NSP)	Laura Mitic, PhD, Bluefield Project to Cure FTD
13:20-13:35	Using Large Data Approaches to Diagnose and Drug Dementia	Judith Steen, PhD, Boston Children's Hospital
13:35-13:55	QUESTIONS and DISCUSSION	Tetsuyuki Maruyama, PhD, KPY Consulting
13:55-14:00	CLOSING REMARKS	Robert Dean, MD, PhD, Robert A. Dean Consulting Tetsuyuki Maruyama, PhD, KPY Consulting
Thursday, October 8, 2020
SESSION II	Part 1: Molecular Biomarkers of ADRD	CHAIR: James Gallarda, PhD, Dx Consultancy
	Part 2: Digital Biomarkers of ADRD	CHAIR: Lampros Kourtis, PhD, Circadic.io
10:00-10:05	Welcome & Introductory Notes	James Gallarda, PhD, Dx Consultancy
10:05-10:20	Liquid Biopsy to Detect Cell Death in Alzheimer's Disease	Yuval Dor, PhD, Hebrew University
10:20-10:35	Validation of a Rapid Non-invasive Diagnostic Test to Predict MCI and early Alzheimer's Disease	Hüseyin Firat, MD, PhD, Amoneta Diagnostics S.A.S.
10:35-10:50	Blood-Based miRNA Diagnostics of Alzheimer's Disease	Bruno Steinkraus, PhD, Hummingbird Diagnostics GmbH
10:50-11:05	Mitochondrial Epigenetics, a Tool for An Early AD Diagnosis	Marta Barrachina, PhD, ADmit Therapeutics S.L.
11:05-11:20	Plasma Cell-Free RNA as Alzheimer's Disease Non-invasive Biomarker	Laura Ibanez, PhD, Washington University
11:20-11:35	Association between Plasma microRNA and other AD Markers in Cognitively Normal Study Participants	Kira Sheinerman, PhD, MBA, Diamir Biosciences
11:35-11:50	Aptamarker Diagnosis of Alzheimer’s Risk Factor in Blood	Gregory Penner, PhD, NeoNeuro
11:50-12:10	QUESTIONS and DISCUSSION	James Gallarda, PhD, Dx Consultancy
12:10-12:15	BREAK
12:15-12:20	Introduction to the session on Digital Biomarkers	Lampros Kourtis, PhD, Circadic.io
12:20-12:35	Novel Virtual Reality Method to Distinguish Apathy from Depression in the Context of Dementia	Ramit Ravona-Springer, MD, Sheba Medical Center
12:35-12:50	Digitally-enhanced Personalized Medicine: Accurate Selection of Subjective Cognitive Decline and Measuring Progression of Mild Cognitive Impairment	Carolina Minguillón, PhD, Barcelonaβeta
12:50-13:05	Smartphone-based Learning and Memory Assessment (LilaTM): Beta Application Development	Chris Edgar, PhD, Cogstate Ltd
13:05-13:20	Alzheimer's Disease Digital Biomarker Discovery: Framingham Cognitive Aging and Dementia Study	Rhoda Au, PhD, Boston University
13:20-13:35	Detecting Cognitive Impairment and Measuring Cognitive Change: Responding to Modern Challenges	Jennifer Rae Myers, PhD, Neurotrack
13:35-13:55	QUESTIONS and DISCUSSION	Lampros Kourtis, PhD, Circadic.io
13:55-14:00	Closing Remarks	Niranjan Bose, PhD, Gates Ventures
Friday, October 9, 2020
Session III	Digital and Ocular Biomarkers	CO-CHAIRS: Nicole Bjorklund, PhD, Alzheimer's Drug Discovery Foundation Eric Siemers, MD, Siemers Integration LLC
17:00-17:05	Welcome & Introductory Notes	Nicole Bjorklund, PhD, Alzheimer's Drug Discovery Foundation
17:05-17:20	Machine Learning Technologies for Advancing Digital Biomarkers for Alzheimer's Disease	Guoliang Xing, DSc, The Chinese University of Hong Kong
17:20-17:35	Threats to Digital Biomarkers and how Data Sharing Can Help	Larsson Omberg, PhD, Sage Bionetworks
17:35-17:50	A Retinal Imaging Biomarker of Alzheimer's Disease	Peter Van Wijngaarden, MBBS, PhD, FRANZCO, Center for Eye Research Australia
17:50-18:05	QUESTIONS & DISCUSSION	Nicole Bjorklund, PhD, Alzheimer's Drug Discovery Foundation Eric Siemers, MD, Siemers Integration LLC
18: 05-18:15	CLOSING REMARKS	Howard Fillit, MD, Alzheimer's Drug Discovery Foundation Niranjan Bose, PhD, Gates Ventures

WELCOME NOTES

Wednesday, October 7, 2020
10:00 US Eastern Time

CONCLUDING REMARKS

Friday, October 9, 2020
18:05 US Eastern Time

Organizers/Hosts

Howard Fillit
Alzheimer’s Drug Discovery Foundation

Niranjan Bose
Gates Ventures

SESSION I

Ocular and Emerging Protein Biomarkers of ADRD, Biomarkers for FTD

This session will cover ocular approaches for the detection of Alzheimer’s disease and transition to the methods to measure the well studied and emerging biomarkers) of Alzheimer’s disease and conclude with notable biomarker efforts in the area of frontotemporal degeneration.

Wednesday, October 7, 2020

10:05 – 14:00 US Eastern Time

Robert Dean
Robert A. Dean Consulting

CO-CHAIR

Tetsuyuki Maruyama
KPY Consulting

CO-CHAIR

Thomas MacGillvray
University of Edinburgh

Delivering Novel Neuro-retinal Biomarkers for the Early Diagnosis of Alzheimer’s Disease

Eliav Shaked
RetiSpec

Findings from the RetiSpec Hyperspectral Imaging System in Individuals with Preclinical and Early Alzheimer’s Disease: A Preliminary Report

Catherine Bornbaum
RetiSpec

Findings from the RetiSpec Hyperspectral Imaging System in Individuals with Preclinical and Early Alzheimer’s Disease: A Preliminary Report

Henrik Zetterberg
Univ of Gothenburg

Fully Automated Plasma Assays as Screening Tests for Alzheimer-related Amyloid Beta Pathology

Stephen Zicha
Fdtn for the NIH

Plasma Aβ as a Predictor of Amyloid Positivity in Alzheimer’s Disease

Wesley Horton
Found. for NIH

Plasma Aβ as a Predictor of Amyloid Positivity in Alzheimer’s Disease

Kaj Blennow
Univ of Gothenburg

Tau and p-tau as Alzheimer Biomarkers – Assays, Methodological Aspects and Clinical Performance

Douglas Galasko
UCSD

TABLOOD: a Biomarker Panel for Direct Assessment in Blood of Alzheimer’s Disease Pathophysiological Hallmarks

Sidney Strickland
The Rockefeller Univ.

Studies on the Plasma Contact System in Alzheimer’s Disease

Erin Norris
The Rockefeller Univ.

Studies on the Plasma Contact System in Alzheimer’s Disease

Amber Murray
Biological Dynamics

Novel Platform for On-Chip Detection of Neuronal Extracellular Vesicle-Bound Peripheral Biomarkers for Alzheimer’s Disease and Other Dementias

Blaine Roberts
Emory University

Validation of Blood-based Biomarkers for the Detection of Brain Amyloid Accumulation before Vlinical Onset of Dementia

Russell Lebovitz
Amprion

Role of Misfolded Synuclein in the Diagnosis and Characterization of Alzheimer’s and Atypical Dementias

Laura Mitic
Bluefield Project

Blood Biomarker Monitoring in Frontotemporal Lobar Degeneration: Neurofilament Surveillance Project (NSP)

Judith Steen
Boston Children’s Hospital

Using Large Data Approaches to Diagnose and Drug Dementia

SESSION II

Part 1: Molecular Biomarkers of ADRD

Part 2: Digital Biomarkers of ADRD

This session will cover the molecular approaches to expand our understanding of Alzheimer’s disease and will be followed by a session on how ubiquitous digital devices such as smart phone use can provide clues in the detection and monitoring of cognition.